NASDAQ:GCTK GlucoTrack (GCTK) Stock Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free GCTK Stock Alerts $0.53 0.00 (0.00%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.52▼$0.5650-Day Range$0.23▼$0.9052-Week Range$0.13▼$0.99Volume93,550 shsAverage Volume185,968 shsMarket Capitalization$14.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get GlucoTrack alerts: Email Address GlucoTrack MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.51% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 7 Articles This WeekInsider TradingAcquiring Shares$230,000 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.73 out of 5 starsMedical Sector846th out of 926 stocksSurgical & Medical Instruments Industry84th out of 91 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for GlucoTrack. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.51% of the float of GlucoTrack has been sold short.Short Interest Ratio / Days to CoverGlucoTrack has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlucoTrack has recently increased by 8.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlucoTrack does not currently pay a dividend.Dividend GrowthGlucoTrack does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GCTK. Previous Next 3.7 News and Social Media Coverage News SentimentGlucoTrack has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for GlucoTrack this week, compared to 1 article on an average week.Search Interest2 people have searched for GCTK on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added GlucoTrack to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GlucoTrack insiders have bought more of their company's stock than they have sold. Specifically, they have bought $230,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.70% of the stock of GlucoTrack is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.92% of the stock of GlucoTrack is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GlucoTrack is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlucoTrack is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlucoTrack has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About GlucoTrack Stock (NASDAQ:GCTK)GlucoTrack, Inc., a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.Read More GCTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GCTK Stock News HeadlinesApril 25, 2024 | insidertrades.comInsider Buying: GlucoTrack, Inc. (NASDAQ:GCTK) Director Purchases 182,540 Shares of StockApril 26, 2024 | investing.comGlucoTrack director Drew Sycoff buys $230k in company sharesMay 1, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…April 26, 2024 | americanbankingnews.comDrew Sycoff Purchases 182,540 Shares of GlucoTrack, Inc. (NASDAQ:GCTK) StockApril 26, 2024 | msn.comNasdaq Rises 0.5%; Tesla Shares Jump After Q1 ResultsApril 25, 2024 | msn.comGlucoTrack And 2 Other Stocks Under $1 Insiders Are BuyingApril 25, 2024 | finance.yahoo.comDirector and 10% Owner Drew Sycoff Acquires 182,540 Shares of GlucoTrack Inc (GCTK)April 22, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENTMay 1, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…April 17, 2024 | finance.yahoo.comGlucoTrack, Inc. (GCTK)April 16, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORINGApril 2, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITORMarch 13, 2024 | nz.finance.yahoo.comUK mortgage arrears rise 50% amid high interest ratesMarch 12, 2024 | globenewswire.comGLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITYFebruary 27, 2024 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Selects Cirtec Medical As Manufacturer For Its Implantable Continuous Blood Glucose MonitorFebruary 27, 2024 | globenewswire.comGLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITORFebruary 13, 2024 | msn.comGlucotrack names Luis Malavé board chairFebruary 13, 2024 | finance.yahoo.comGLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORSJanuary 3, 2024 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Announces Early Accuracy Data For Its Implantable Continuous Glucose MonitorJanuary 2, 2024 | msn.comGlucoTrack stock jumps 13% on preclinical update for glucose monitorJanuary 2, 2024 | finance.yahoo.comGLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITORDecember 1, 2023 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Announces 180-day Extension To Regain Compliance With Nasdaq Minimum Bid Price RequirementDecember 1, 2023 | msn.comNasdaq grants additional 180 days to Glucotrack to regain complianceNovember 30, 2023 | finance.yahoo.comGLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTNovember 13, 2023 | finance.yahoo.comGLUCOTRACK ANNOUNCES SHAREHOLDER UPDATENovember 10, 2023 | msn.comWhy Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day SessionOctober 12, 2023 | finance.yahoo.comGLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITORSee More Headlines Receive GCTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlucoTrack and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/01/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:GCTK CUSIPN/A CIK1506983 Webwww.glucotrack.com Phone(201) 842-7715Fax972-8675-7850Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-172.38% Return on Assets-127.42% Debt Debt-to-Equity Ratio0.06 Current Ratio3.22 Quick Ratio3.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book3.56Miscellaneous Outstanding Shares26,760,000Free Float22,020,000Market Cap$14.30 million OptionableNot Optionable Beta0.29 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Paul V. Goode Ph.D. (Age 55)Chief Executive Officer Comp: $225kMr. Mark Tapsak Ph.D. (Age 55)Vice President of Technology Comp: $165kMs. Drinda Benjamin (Age 48)Vice President of Marketing Mr. James P. Thrower Ph.D. (Age 54)Vice President of Engineering Comp: $230kMr. Avner Gal MBA (Age 70)MSc.EE, Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board Comp: $187.39kMr. David Malka BA (Age 59)Co-Founder Comp: $191.86kMr. James S. Cardwell (Age 63)Chief Financial Officer More ExecutivesKey CompetitorsPetVivoNASDAQ:PETVSTRATA Skin SciencesNASDAQ:SSKNMicrobot MedicalNASDAQ:MBOTNEXGELNASDAQ:NXGLBiotricityNASDAQ:BTCYView All CompetitorsInsidersDrew SycoffBought 182,540 shares on 4/22/2024Total: $230,000.40 ($1.26/share)View All Insider Transactions GCTK Stock Analysis - Frequently Asked Questions How have GCTK shares performed in 2024? GlucoTrack's stock was trading at $0.2615 at the start of the year. Since then, GCTK shares have increased by 104.4% and is now trading at $0.5344. View the best growth stocks for 2024 here. Are investors shorting GlucoTrack? GlucoTrack saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 106,200 shares, an increase of 8.3% from the March 31st total of 98,100 shares. Based on an average trading volume of 169,100 shares, the short-interest ratio is currently 0.6 days. Approximately 0.5% of the company's stock are short sold. View GlucoTrack's Short Interest. When is GlucoTrack's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our GCTK earnings forecast. How were GlucoTrack's earnings last quarter? GlucoTrack, Inc. (NASDAQ:GCTK) announced its quarterly earnings data on Thursday, March, 28th. The company reported ($0.10) earnings per share (EPS) for the quarter. How do I buy shares of GlucoTrack? Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GCTK) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmith[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
